On this episode of Stock Spotlight, Michael analyzes Medpace Holdings (MEDP), a unique player in the contract research organization (CRO) space. Unlike industry giants focused on big pharma, Medpace specializes in small to mid-sized firms - a double-edged sword that grants pricing power, but also exposes it to biotech funding volatility.

With a potential return to double-digit growth in 2026, Medpace meets the criteria for a Quality Growth company, but its narrow moat, lack of true market leadership and poor Glassdoor ratings raise red flags. From a valuation standpoint, Medpace appears modestly undervalued, yet technical indicators signal caution.

Is Medpace a hidden gem in the healthcare sector or a high-risk bet reliant on biopharma funding stability? Tune in as Michael unpacks his strategy for this niche CRO.

----------------------------------------------------------------

00:00 Intro

00:38 Investment Checklist & Database

02:31 Business & Industry Overview

13:23 Business Model & Quality Growth Attributes

22:19 Financial Statement Overview

30:05 Management & Ownership Structure

34:48 Growth Areas & Risk Factors

37:46 KPIs to Track

38:43 Valuation & Technical Analysis

43:46 Episode Takeaways

44:36 Outro

----------------------------------------------------------------

Intro Music: Andrey Rossi – Seize the Day

Outro Music: Ra – Prospect

*Music provided by Uppbeat Premium

Follow me on X: https://twitter.com/invest091

Subscribe to my YouTube channel: https://www.youtube.com/@stockspotlightpodcast

----------------------------------------------------------------

Disclosure: The host of Stock Spotlight is not a licensed financial advisor. The information and opinions shared during the show are for entertainment purposes only.

Medpace Holdings, Inc. (MEDP): Undervalued CRO or Funding-Dependent Risk?

Stock Spotlight

Medpace Holdings, Inc. (MEDP): Undervalued CRO or Funding-Dependent Risk?